Skip to content

Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation

Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00939744
Acronym
EAU2
Enrollment
130
Registered
2009-07-15
Start date
2009-05-31
Completion date
2015-10-31
Last updated
2015-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstetric Labor Complications, Prolonged Pregnancy

Keywords

contractile activity, eicosanoids, pregnant women, obstetrics complications

Brief summary

Recent studies show that EET and 20-HETE have important biological effects, particularly in the vascular system. The investigators studied the effect of eicosanoids on the gravid rat uterus. The results suggest that 20-HETE had an tocolytics effect on gravid uterus. In the previous study, we demonstrated that the enzymes of the pathway of EET were present in human uterine tissues. Moreover, the addition of an inhibitor of degradation of EET had an tocolytic effect on the human myometrium, as the exogenous addition of 8.9, 14,15-EET and 20-HETE. Objectives: Primary objective: To compare the balance of different metabolic pathways of arachidonic acid (AA) of the pregnant human myometrium in pathological situations (preterm labor, uterine atony, prolonged pregnancy). Specific objectives: i) To study the effect of derived from the AA on in vitro contractile activity of normal and pathological uterine tissues, and ii) detect and quantify the different sub-products of metabolism of AA in the uterine tissues (myometrium, fetal membranes and placenta). The management of uterine contraction is in the heart of modern obstetrics year, yet the progress made in other specialties, based on the study of smooth muscle have not yet been transposed in obstetrics. A better understanding of systems for regulating the contraction is important in terms of 1) new physiological knowledge, but it could also be the source of 2) modification of strategies to take care of premature delivery (new Tocolytic), or 3) improving the efficiency of uterine muscle during delivery or 4) for treatment of patients with prolonged pregnancy.

Detailed description

It is a clinical study with a slope fundamental aims to examine the metabolic pathways of AA of human myometrium and their functional roles according to their clinical profile divided into three contractile pathological situations - threat of premature delivery, dynamic dystocia, prolonged pregnancy - and two groups of patients at term: a group before work and group work. The sampling method. After birth, a biopsy will be perform from the lower segment of the uterus. After caesarean sections of membrane and placenta are collected. The substances studied during isometric tension tests are part of the three degradation pathways of the AA. 1. new eicosanoids in cumulative dose (8,9-EET, 11,12-EET, 14,15-EET, 20-HETE), and in combination 2. enzyme inhibitors of the eicosanoids pathway (AUDA, MS-PPOH, DDMS), and the COX and LOX pathways (indomethacin), alone or in combination.

Interventions

None listed

Sponsors

Fonds de la Recherche en Santé du Québec
CollaboratorOTHER_GOV
Université de Sherbrooke
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* all women who will have a c-section

Exclusion criteria

* induction of labor, * child with malformation, * birth weight less than 2500 grams or greater than 4500g

Design outcomes

Primary

MeasureTime frame
effect of eicosanoids on contractile activity of myometrium of pregnant women with pathological situationsduring c-section

Secondary

MeasureTime frame
effect of enzymatic inhibitors on contractile activity of myometrium from pregnant women with pathological situationsduring c-section
detection of enzymes from the different pathwaysafter c-section
quantification of eicosanoids in different tissuesafter c-section

Countries

Canada

Contacts

Primary ContactStéphanie Corriveau, BSc
stephanie.corriveau@usherbrooke.ca819 346-1110
Backup ContactSimon Blouin, PhD
syblouin.chus@ssss.gouv.qc.ca819 346-1110

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026